Beth Israel Deaconess Medical Center



HARVARD MEDICAL SCHOOL **TEACHING HOSPITAL**

RACIAL AND ETHNIC DISPARITIES IN OPIOID PRESCRIPTIONS IN BENIGN AND MALIGNANT PANCREATIC DISEASE IN **THE UNITED STATES, 2006-2015**

Nicole McHenry BA¹, Awais Ahmed MD¹, Ishani Shah MD¹, Shivani Gulati, Steven D. Freedman MD PhD¹, Judy Nee MD¹, Anthony Lembo MD¹, Sunil G. Sheth MD¹

1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA

Introduction

- Racial-ethnic disparities in pain management are well established, but not for patients with pancreatic disea
- In this study, we seek to evaluate racial-ethnic disparit opioid prescriptions for patients with acute and chron pancreatitis and pancreatic cancer.

Methods


- We used data from the National Ambulatory Medical Survey (NAMCS) to examine opioid prescriptions duri ambulatory visits by adult pancreatic disease patients between 2006 and 2015.
- Diagnoses were determined by ICD-9 codes 557.0 and for pancreatitis and 157 for pancreatic cancer.
- Visits by patients with comorbid painful conditions associated with opioid use were excluded.
- Opioid medications were identified using Cerner Mult Lexicon Plus Drug Database prescription codes.
- We then compared differences in opioid prescriptions race, ethnicity, and sex.

• While racial-ethnic disparities in opioid prescriptions were observed in pancreatitis patient visits, none were seen in pancreatic cancer patient visits.

opioid provision in the treatment of malignant and terminal pancreatic disease.

II- ease. rities in	 We identified 421 outpatient visits by adults pancreatic disease and eliminated 18 patient with comorbid painful conditions or for age
nic	 Our analysis included 207 pancreatitis and 19 pancreatic cancer patient visits.
l Care ing	 No sex differences were found among pancreatitis (p=0.78) or pancreatic cancer pa visits (p=0.57) (Table 1).
d 557.1	 Opioids were prescribed at 58% of non-Hispa Black, 27% of non-Hispanic White, and 19% of Hispanic pancreatitis patient visits (p=0.05) (7 2).
ltum	 Opioid prescriptions were less common in vis by Hispanic compared to non-Hispanic pancreatitis patients (OR 0.35, 95% CI 0.14-0 p=0.03) and there was a trend toward higher rates in non-Hispanic Black versus non-Hispa White patient visits (Table 3).
is by	 No racial-ethnic differences in opioid prescriptions were seen among pancreatic ca patient visits.
	Conclusions

• These findings suggest racial and ethnic bias in opioid prescription practices for patients with painful but benign pancreatic disease, but there may be a lower threshold for



	Contact Information
	Nicole McHenry, BA nmchenry@bidmc.harvard.edu
for	330 Brookline Ave Boston, MA 02215